Recent Advances in Improved Efficacies of Gold Nano-Formulations in Treatment of Skin Cancer: A Systematic Review Publisher Pubmed

Summary: Gold nanoparticles enhance skin cancer treatment, review finds, offering targeted therapy potential. #SkinCancer #Nanotechnology

Heydari M¹ ; Saifi M¹ ; Ghanbarimovahed M² ; Salari N³ ; Faghihi SH⁴ ; Mohammadi M⁵
Source: Archives of Dermatological Research Published:2025

Abstract

Skin cancer is the commonest malignancy for the population. Conventional skin cancer treatments include chemotherapy and surgery, but a large number of the chemotherapeutic drugs applied currently have undesirable possessions. The aim of this study is to provide a complete and acute assessment of the antitumor capability of gold nano-formulations in skin cancer as a new and more effectual delivery system for targeted therapy. In this systematic review, we conducted our first search in December 2021. In order to find related studies, 3 databases PubMed, Scopus and ScienceDirect. In order to maintain comprehensiveness in the search, no time limit was considered in the search process and finally the information obtained from the search was transferred to the information management software (EndNote). In order to maximize the number of articles that were related to our topic, a list of references identified in relevant articles was also manually searched and reviewed. Our final search was updated in late December 2021. There was evidence for a correlation between anticancer activities and treatment with gold nano-formulations. Additionally, studies shown that specific functionalization of the gold nanoparticles (Au NPs) which increase targetability to specific populations of cells could increase the application of Au NPs to the effective delivery of drugs to tumor cells. Our study demonstrated that gold nano-formulations are possible candidates for skin cancer treatment and might provide additional support for the clinical use of these anticancer agents in the future. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2025.